Valuation: Beta Bionics, Inc.

Market Cap 1.08B 965M 893M 809M 1.51B 103B 1.54B 10.75B 4.25B 53.73B 4.05B 3.97B 170B P/E 2026 *
-10.2x
P/E 2027 * -9.84x
Enterprise Value 933M 834M 772M 699M 1.31B 88.76B 1.33B 9.29B 3.67B 46.42B 3.5B 3.43B 147B EV / Sales 2026 *
7.5x
EV / Sales 2027 * 5.66x
Free-Float
99.19%
Yield 2026 *
-
Yield 2027 * -
1 day+7.05%
1 week+21.79%
Current month+8.06%
1 month-4.65%
3 months+29.40%
6 months+83.62%
Current year-32.69%
1 week 17.17
Extreme 17.17
21.18
1 month 16.32
Extreme 16.32
21.7
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/26 Sell

Executive/Senior Manager

-775 0.0014%
01/10/26 Sell

Executive/Senior Manager

-370 0.0007%
22/09/26 Sell

Director

-6,430 0.0143%
Change 5-day change 1-year change 3-year change Capi.($)
+7.05%+21.79%-2.10% - 1.08B
+1.64%+0.81%+19.63%+55.60% 253B
+1.07%+3.81%+4.47%+20.29% 164B
-0.15%+4.26%-17.36%+74.03% 157B
-0.24%+1.18%-54.92%-8.44% 66.06B
-1.50%+0.44%+8.59%+67.34% 51.52B
-0.46%+1.76%-14.77%-8.05% 52.64B
+1.67%+3.83%+19.00%+44.25% 52.2B
+1.67%+3.57%+18.87%+68.69% 49.61B
+0.51%+5.00%+26.84%+86.53% 44.8B
Average +1.12%+4.78%+0.82%+44.47% 89.16B
Weighted average by Cap. +0.73%+2.67%+2.41%+46.13%

Financials

2026 *2027 *
Net sales 124M 111M 103M 93.15M 174M 11.83B 177M 1.24B 490M 6.19B 467M 457M 19.59B 183M 163M 151M 137M 256M 17.38B 260M 1.82B 719M 9.09B 685M 671M 28.78B
Net income -93.69M -83.78M -77.51M -70.18M -131M -8.91B -134M -933M -369M -4.66B -352M -344M -14.76B -103M -92.45M -85.53M -77.44M -145M -9.84B -147M -1.03B -407M -5.14B -388M -380M -16.29B
Net Debt -147M -131M -121M -110M -206M -13.96B -209M -1.46B -578M -7.3B -551M -539M -23.12B -46.25M -41.36M -38.27M -34.65M -64.84M -4.4B -65.91M -460M -182M -2.3B -174M -170M -7.29B
Projected Income Statement - Annual - Beta Bionics, Inc.
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
26/10/26 $20.51 +7.05% 1,630,975
23/10/26 $19.16 -0.93% 827,848
22/10/26 $19.34 +5.11% 685,201
21/10/26 $18.40 +3.72% 1,440,594
20/10/26 $17.74 +5.34% 656,725
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Beta Bionics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
20.51USD
Average target price
24.24USD
Spread / Average Target
+18.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Beta Bionics, Inc.
  1. Stock Market
  2. Stocks
  3. BBNX Stock